Skip to main content
Innovent Biologics, Inc. (IVBXF)
OTCMKTS · Delayed Price · Currency is USD
5.98
+0.01 (0.08%)
Apr 23, 2025, 4:00 PM EDT

Innovent Biologics Revenue

In the year 2024, Innovent Biologics had annual revenue of 9.42B CNY with 51.82% growth. Innovent Biologics had revenue of 5.47B in the half year ending December 31, 2024, with 136.09% growth.

Revenue
9.42B CNY
Revenue Growth
+51.82%
P/S Ratio
8.47
Revenue / Employee
1.66M CNY
Employees
5,659
Market Cap
10.93B USD

Revenue Chart

* This company reports financials in CNY.

History

Fiscal Year End Revenue Change Growth
Dec 31, 20249.42B3.22B51.82%
Dec 31, 20236.21B1.65B36.21%
Dec 31, 20224.56B286.65M6.71%
Dec 31, 20214.27B425.91M11.08%
Dec 31, 20203.84B2.80B266.94%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
SS Innovations International 20.65M
Endo Inc. 1.76B
Veradigm 588.02M
Northwest Biotherapeutics 1.38M
Elite Pharmaceuticals 70.00M
Glass House Brands 200.90M
BioStem Technologies 301.83M
American Oncology Network 1.76B
Revenue Rankings

Innovent Biologics News

More News